# RMP-A03 Ocular Suspension in Patients With Pterygium

> **NCT05794204** · PHASE2 · COMPLETED · sponsor: **Suzhou Raymon Pharmaceuticals Company, Ltd.** · enrollment: 77 (actual)

## Conditions studied

- Pterygium

## Interventions

- **DRUG:** RMP-A03 - Dose 1
- **DRUG:** RMP-A03 - Dose 2
- **DRUG:** RMP-A03 Placebo

## Key facts

- **NCT ID:** NCT05794204
- **Lead sponsor:** Suzhou Raymon Pharmaceuticals Company, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-06-09
- **Primary completion:** 2024-01-12
- **Final completion:** 2024-01-12
- **Target enrollment:** 77 (ACTUAL)
- **Last updated:** 2024-12-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05794204

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05794204, "RMP-A03 Ocular Suspension in Patients With Pterygium". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05794204. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*